Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 10 | 2017 | 3344 | 0.910 |
Why?
|
| Brain Neoplasms | 15 | 2017 | 8776 | 0.730 |
Why?
|
| Spectrum Analysis, Raman | 3 | 2014 | 229 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2017 | 34151 | 0.610 |
Why?
|
| Astrocytoma | 2 | 2015 | 794 | 0.480 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2012 | 31 | 0.470 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 189 | 0.420 |
Why?
|
| Head | 1 | 2017 | 845 | 0.420 |
Why?
|
| Cell Tracking | 1 | 2012 | 147 | 0.420 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2011 | 145 | 0.400 |
Why?
|
| Adenoma | 2 | 2011 | 2130 | 0.380 |
Why?
|
| Ciliary Body | 1 | 2009 | 176 | 0.360 |
Why?
|
| Echo-Planar Imaging | 2 | 2014 | 664 | 0.350 |
Why?
|
| Neuronavigation | 1 | 2009 | 175 | 0.340 |
Why?
|
| Mesencephalon | 1 | 2009 | 322 | 0.330 |
Why?
|
| Radiation Dosage | 1 | 2017 | 2041 | 0.320 |
Why?
|
| Uveal Neoplasms | 1 | 2009 | 317 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 20308 | 0.300 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 1508 | 0.290 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2017 | 3418 | 0.280 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 1468 | 0.270 |
Why?
|
| Critical Care | 1 | 2017 | 2473 | 0.260 |
Why?
|
| Dacarbazine | 3 | 2015 | 585 | 0.250 |
Why?
|
| Image Enhancement | 5 | 2012 | 2975 | 0.250 |
Why?
|
| Skin | 2 | 2017 | 4325 | 0.250 |
Why?
|
| Pituitary Neoplasms | 1 | 2011 | 1287 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2012 | 2641 | 0.230 |
Why?
|
| Deep Brain Stimulation | 1 | 2009 | 672 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2017 | 4057 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 9584 | 0.210 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 2483 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 3 | 2012 | 1019 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2748 | 0.170 |
Why?
|
| Algorithms | 8 | 2012 | 13647 | 0.170 |
Why?
|
| Sarcoma | 1 | 2008 | 1854 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2017 | 8877 | 0.160 |
Why?
|
| Tomography, Spiral Computed | 1 | 2017 | 293 | 0.140 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 7026 | 0.130 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2006 | 98 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13714 | 0.130 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 14836 | 0.120 |
Why?
|
| Survival Rate | 3 | 2017 | 13202 | 0.110 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 19423 | 0.110 |
Why?
|
| Glioma | 4 | 2013 | 3292 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2015 | 1688 | 0.110 |
Why?
|
| Stroke | 2 | 2012 | 9256 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2011 | 2357 | 0.100 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2011 | 141 | 0.100 |
Why?
|
| Middle Aged | 15 | 2017 | 213752 | 0.100 |
Why?
|
| Brain Chemistry | 1 | 2014 | 1019 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2017 | 61932 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2012 | 368 | 0.100 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2009 | 43 | 0.100 |
Why?
|
| Medicine, Traditional | 1 | 2009 | 91 | 0.090 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2008 | 14 | 0.090 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2008 | 18 | 0.090 |
Why?
|
| Humans | 33 | 2017 | 708843 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2012 | 543 | 0.090 |
Why?
|
| Vagus Nerve | 1 | 2011 | 444 | 0.090 |
Why?
|
| Female | 20 | 2017 | 375205 | 0.090 |
Why?
|
| Microelectrodes | 1 | 2009 | 301 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 8968 | 0.090 |
Why?
|
| Male | 16 | 2017 | 349524 | 0.090 |
Why?
|
| Microscopy | 1 | 2013 | 873 | 0.090 |
Why?
|
| Brain | 9 | 2014 | 24969 | 0.090 |
Why?
|
| ROC Curve | 1 | 2015 | 3518 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2012 | 1151 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2009 | 358 | 0.080 |
Why?
|
| Diagnosis, Differential | 6 | 2011 | 13274 | 0.080 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 381 | 0.080 |
Why?
|
| Subthalamic Nucleus | 1 | 2009 | 174 | 0.080 |
Why?
|
| Heme Oxygenase-1 | 1 | 2009 | 382 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2014 | 3984 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2008 | 1530 | 0.080 |
Why?
|
| Amnesia, Anterograde | 1 | 2006 | 23 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2012 | 1490 | 0.070 |
Why?
|
| Neurilemmoma | 1 | 2011 | 524 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2006 | 56 | 0.070 |
Why?
|
| Herpesvirus 6, Human | 1 | 2006 | 93 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2017 | 71483 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2011 | 2328 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2015 | 10507 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2012 | 3859 | 0.070 |
Why?
|
| Adult | 15 | 2015 | 211041 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1829 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 656 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2007 | 3700 | 0.070 |
Why?
|
| Brain Mapping | 3 | 2009 | 6545 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 2067 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2017 | 3418 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 518 | 0.060 |
Why?
|
| Contrast Media | 1 | 2017 | 5267 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 2020 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1228 | 0.060 |
Why?
|
| Quinazolines | 1 | 2010 | 1420 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 959 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 641 | 0.060 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 565 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3693 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 18375 | 0.060 |
Why?
|
| Epidermal Cyst | 1 | 2002 | 67 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 2007 | 601 | 0.050 |
Why?
|
| Brain Abscess | 1 | 2002 | 118 | 0.050 |
Why?
|
| Scoliosis | 1 | 2008 | 684 | 0.050 |
Why?
|
| Piperidines | 1 | 2010 | 1582 | 0.050 |
Why?
|
| Lipids | 1 | 2012 | 3246 | 0.050 |
Why?
|
| Artifacts | 1 | 2009 | 1904 | 0.050 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 868 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2008 | 1770 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 985 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 1449 | 0.050 |
Why?
|
| Neuroglia | 1 | 2005 | 930 | 0.050 |
Why?
|
| Software | 1 | 2012 | 4345 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15252 | 0.040 |
Why?
|
| Disease Progression | 1 | 2014 | 13298 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6151 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 28919 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12292 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16959 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 13536 | 0.030 |
Why?
|
| Animals | 5 | 2013 | 170486 | 0.030 |
Why?
|
| Hematoxylin | 1 | 2013 | 63 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 73 | 0.030 |
Why?
|
| Aged | 7 | 2012 | 161488 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 22989 | 0.030 |
Why?
|
| Mice | 4 | 2013 | 80876 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 11126 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 50597 | 0.030 |
Why?
|
| Software Validation | 1 | 2012 | 61 | 0.030 |
Why?
|
| Color | 1 | 2013 | 309 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11253 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6338 | 0.030 |
Why?
|
| Melanoma | 1 | 2008 | 5194 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 5266 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 996 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2165 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 6497 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5135 | 0.020 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 66 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 15053 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 41038 | 0.020 |
Why?
|
| Diverticulitis | 1 | 2010 | 162 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 914 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 766 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 387 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 2687 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 559 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 147 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 10525 | 0.020 |
Why?
|
| Urban Health | 1 | 2008 | 537 | 0.020 |
Why?
|
| Peru | 1 | 2008 | 835 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 991 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 58184 | 0.020 |
Why?
|
| Neurons | 1 | 2005 | 9385 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 871 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 4883 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 12183 | 0.020 |
Why?
|
| Diffusion | 1 | 2006 | 828 | 0.020 |
Why?
|
| Risk Factors | 1 | 2011 | 69553 | 0.020 |
Why?
|
| Pulvinar | 1 | 2003 | 23 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 1875 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 490 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2006 | 559 | 0.010 |
Why?
|
| HIV Infections | 1 | 2008 | 15538 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1336 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2317 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1055 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2427 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1392 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1136 | 0.010 |
Why?
|
| Temporomandibular Joint | 1 | 2003 | 181 | 0.010 |
Why?
|
| Wrist | 1 | 2003 | 207 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2008 | 2680 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 19800 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 5045 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 1294 | 0.010 |
Why?
|
| Orbit | 1 | 2003 | 430 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 2715 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4353 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2011 | 1661 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2007 | 1623 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 5041 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 1837 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8896 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 55940 | 0.010 |
Why?
|
| Poverty | 1 | 2008 | 2557 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9927 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 2401 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3627 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 4062 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 5197 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8024 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 3876 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 6766 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6170 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 5703 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2003 | 5781 | 0.010 |
Why?
|
| Child | 1 | 2008 | 73636 | 0.000 |
Why?
|
| Adolescent | 1 | 2008 | 84718 | 0.000 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_